Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Emtricitabine, Rilpivirine, Tenofovir Drug Combination

Known as: Combination, Emtricitabine-Rilpivirine-Tenofovir Drug, Emtricitabine, Rilpivirine, Tenofovir Drug Combination [Chemical/Ingredient], Drug Combination, Emtricitabine-Rilpivirine-Tenofovir 
A pharmaceutical preparation that contains emtricitabine, rilpivirine and tenofovir disoproxil fumarate. It is used to treat HIV INFECTIONS.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Background: Prior studies using reverse transcriptase inhibitors to treat a human betaretrovirus (HBRV) in patients with primary… Expand
Is this relevant?
2018
2018
Objectives To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their antiretroviral… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
It is estimated that up to 14% of patients with HIV have diabetes mellitus (DM), which is a determinant risk factor for the… Expand
Is this relevant?
2017
2017
Abstract Background Differences between regimens in the frequency of transient episodes of viremia (viral blips) as well as the… Expand
Is this relevant?
2016
2016
There is a need to improve antiretroviral options in Africa. This study shows switching from a neviripine-based treatment to co… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
BACKGROUND Completion rates for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) are low. We investigated the… Expand
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2012
2012
Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
2012
2012
Rilpivirine (RPV) is a new non‐nucleoside reverse transcriptase inhibitor (NNRTI) which has shown non‐inferiority to efavirenz… Expand
Is this relevant?